New York Times, December 19, 2018
Jamie Condliffe

Links

Read the Full Article

GlaxoSmithKline and Pfizer plan to merge their consumer-health divisions in a joint venture that the companies said would be the world’s largest maker of over-the-counter products like pain relievers, toothpastes, cold treatments, vitamins and dietary supplements.

GlaxoSmithKline, which is based on Britain, will own 68 percent of the new entity; Pfizer, which has its headquarters in New York, will own the balance, according to a news release announcing the venture on Wednesday.

The companies said they expected the deal, which is subject to shareholder and regulatory approval, to close in the second half of next year, and that plans call for it to be spun off within five years though a listing on the British stock markets.

The divisions being merged had combined global sales of $12.7 billion in 2017. As one company, they would be the world’s largest over-the-counter supplier, with a market share of 7.3 percent, according to GlaxoSmithKline. [...]

health care costs market pharmaceuticals public health